Skip to content
Screener

EyePoint, Inc. EYPT Total Current Liabilities

Total Current Liabilities at other companies

Merck & Co. logo
Merck & Co.MRK
$27.73B+6.5%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$5.53B+50.8%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$47.68M+25.7%
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
$49.57M+60.6%
Regenxbio logo
RegenxbioRGNX
$82.62M-30.9%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
$43.4M+61.4%

Other financials

Income statement

See full
Revenue$507.0K-90.5%
Gross profit$9.8M-30.1%
Operating income-$97.4M-56.5%
Net income-$94.5M-59.0%
EPS (diluted)-$1.09-28.2%

Balance sheet

See full
Cash & equivalents$110.5M+55.3%
Total debt$22.4M-5.7%
Total equity$166.4M-32.4%
Total assets$228.2M-24.2%

Cash flow

See full
Operating cash flow-$62.3M+0.4%
CapEx$1.2M-1.6%
Free cash flow-$63.5M+0.4%

Valuation

See full
Market cap$1.2B+69.1%
Enterprise value$1.11B+67.9%
P/S429.4×+416×

Profitability

See full
Operating margin-11,365.2%-11,754pp
Net margin-10,994.7%-11,355pp
FCF margin-9,726.7%-10,132pp

Returns & leverage

See full
Return on equity-148.7%-13,871pp
Debt / equity0.1×0.0×
Current ratio4.5×-3.5×

Where this comes from

Reported directly by EyePoint, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The source filing: EyePoint, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335037
Line itemJune 30, 2026December 31, 2025
Accounts payable$17,267$10,490
Accrued expenses21,99724,394
Other current liabilities2,6792,140
Total current liabilities41,94337,024
Operating lease liabilities – noncurrent19,81420,772
Other noncurrent liabilities2387
Total liabilities61,78057,883
Contingencies (Note 12)

Item 1. Unaudited Financial Statements

FAQ

What is EyePoint, Inc.'s total current liabilities?
EyePoint, Inc. (EYPT) reported total current liabilities of $41.94M in Q2 2026.
How has EyePoint, Inc.'s total current liabilities changed year-over-year?
EyePoint, Inc.'s total current liabilities increased by 26.4% year-over-year, from $33.18M to $41.94M.
What is the long-term trend for EyePoint, Inc.'s total current liabilities?
Over 5 years (2020 to 2025), EyePoint, Inc.'s total current liabilities has grown at a 20.0% compound annual growth rate (CAGR), from $14.89M to $37.02M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.

Ask your AI about EyePoint, Inc.'s total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude